Drug Type Autologous CAR-T |
Synonyms ET019002-T Cell Therapy, ET019002-T Cells, ET 019002 |
Target |
Action modulators |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Non-Hodgkin Lymphoma | Phase 1 | China | 28 Mar 2020 | |
| Burkitt Lymphoma | Phase 1 | - | 19 Aug 2018 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | - | 19 Aug 2018 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | - | 19 Aug 2018 |





